http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201918259-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2018-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_829c969b1e95d25def8b996028dd165b |
| publicationDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201918259-A |
| titleOfInvention | Treatment of idiopathic pulmonary interstitial fibrosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist polypeptide |
| abstract | The present invention relates to the use of a polypeptide compound having a double agonistic effect of a glucagon-like peptide-1 receptor (GLP-1R) and a glucagon receptor (GCGR), It has high enzymatic stability, high biological activity and no adverse reactions. It can significantly inhibit the fibroblastic transformation and proliferation of human lung epithelial cells induced by TGF-β1, and can significantly improve bleomycin-induced pulmonary fibrosis in mice. degree. Such dual-target agonist polypeptides are useful for the prevention or treatment of pulmonary diseases characterized by fibrotic symptoms. |
| priorityDate | 2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 169.